Evaluation of Pharmaceutical Services and Their Effects Provided by Clinical Pharmacists under the Medical Insurance Diagnosis-intervention Packet Payment Model
Objective The aim of this study is to explore the feasibility,rationality under the diagnosis-intervention packet(DIP)payment model,with the goal of reducing per capita hospitalization costs by lowering medication expenses for patients covered by health insurance.Methods In this study,patients with respiratory tuberculosis classified under the health insurance system were selected from Jiangxi Provincial Chest Hospital where clinical pharmacists provided pharmaceutical services during their hospitalization.The average data of similar diseases covered by health insurance in the hospital between 2020 and 2022 were used as the control group.The intervention group consisted of 100 patients in the same disease group who received pharmaceutical services from clinical pharmacists during their hospitalization.In the intervention group,the clinical pharmacists and doctors established a specialized pharmaceutical service team and developed a medication treatment plan based on the previous regional health insurance payment for the included diseases.The differences in per capita total costs,medication proportion,and length of stay between the two groups were analyzed and compared.Results After the intervention,the per capita total costs and medication proportion of the respiratory tuberculosis 3-group in the intervention group significantly decreased(P<0.01),but there was no statistically significant change in the length of stay(P>0.05).Conclusion Clinical pharmacists,utilizing their professional knowledge and combining it with the DIP payment mechanism,clinical pathways of diseases and relevant pharmaceutical data of medical institutions,successfully optimized medication treatment plans and effectively reduced health insurance medication expenses for diseases targeted by hospital interventions,promoting rational medication use.
万方数据
维普
